REFERENCES
- Anderson, S., Hauck, W. W. (1990). Considerations of in dividuals bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 8:259–273.
- Chow, S. C., Liu, J. P. (2008). Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd ed. New York, NY: Chapman and Hall/CRC Press, Taylor & Francis.
- Chow, S. C., Hsieh, T. C., Chi, E., Yang, J. (2010). A Comparison of moment-based and probability-based criteria for assessment of follow-on biologics. Journal of Biopharmaceutical Statistics 30:31–45.
- Chow, S. C., Liu, J. P. (1995). Statistical Design and Analysis in Pharmaceutical Science. New York, NY: Marcel Dekker.
- Church, J. D., Harris, B. (1970). The estimation of reliability from stress–strength relationships. Technometrics 12:49–54.
- Enis, P., Geisser, S. (1971). Estimation of the probability that Y < X. Journal of the American Statistical Association 66:162–168.
- Esinhart, J. D., Chinchilli, V. M. (1994). Extension to the use of tolerance intervals for assessment of individual bioequivalence. Journal of Biopharmaceutical Statistics 4:39–52.
- European Medicines Agency. (2001). Note for Guidance on the Investigation of Bioavailability and Bioequivalence. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/EWP/QWP/1401/98. London, UK.
- European Medicines Agency. (2005a). Guidance on Similar Biological Medicine Products. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMP/437/04. London, UK.
- European Medicines Agency. (2005b). Draft Guidance on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Drug Substance: Quality Issues. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMU/49348/05. London, UK.
- Food and Drug Administration. (1992). Guidance on Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Cross-Over Design. Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD.
- Food and Drug Administration. (2000). Guidance for Industry: Bioavalability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations. Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD.
- Food and Drug Administration. (2001). Guidance for Industry on Statistical Approaches to Establishing Bioequivalence. Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD.
- Food and Drug Administration. (2003). Guidance on Biovailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations. Rockville, MD: Center for Drug Evaluation and Research, U.S. Food and Drug Adiministration.
- Food and Drug Administration. (2005). Q5E Comparability of Biotechnological/Biological Products Subject to Change in Their Manufacturing Process. Rockville, MD: U.S. Food and Drug Administration.
- Kang, S. H., Chow, S. C. (2013). Statistical assessment of biosimilarity based on relative distance between follow-on biologics. Statistics in Medicine 32: 382–392.
- Schall, R., Luus, H. G. (1993). On population and individual bioequivalence. Statistics in Medicine 12:1109–1124.
- Tse, S. K., Chang, Y. J., Su, W. L., Chow, S. C., Hsiung, C., Lu, Q. S. (2006). Statistical quality control process for traditional Chinese medicine. Journal of Biopharmaceutical Statistics 16:861–874.